Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Price drop

    by ltdobanion Apr 26, 2016 3:57 PM

    I see terry has responded to my post. He is on permanent ignore so I have no idea what he said nor do I care.

  • Reply to

    The Only Solution

    by bohemianclubman Apr 27, 2016 11:01 AM

    All anyone has to do is put the idiot on ignore and not read anything he posts. It cleans up the message board and really, who cares what he says? Why get upset at a moron.

  • What is holding Insmed back? Must be hedge funds getting washed out in other investments forced to sell to cover margin, or it could be short sellers coming back for more after profiting twice with SRPT in the past week.
    pianoman

    Sentiment: Strong Buy

  • ......was posted earlier today on this board. Here are the numbers.....DOWN approximately 600,000 shares. This is the lowest share interest figure in over a year.

    Settlement Date Short Interest Avg Daily Share Volume Days To Cover
    4/15/2016 3,908,509 431,447 9.059071
    3/31/2016 4,522,509 378,673 11.943046

  • Reply to

    Terry - your ARDM recommendation vs INSM

    by arikaycerocks Apr 26, 2016 6:31 PM

    Pulmaquin (liposomal ciprofloxacin) poses too many questions for me bwd.

    Last April's report on the efficacy against MAC and MAB in vitro was intriguing. But given the WHO guidance (below) one wonders if they also tested it against M.tuberculosis and it came up short.

    From a 2010 article on the mechanism of ciprofloxacin resistance -

    [ There is a small set of drugs commonly used to treat P. aeruginosa infection, including ciprofloxacin, tobramycin, gentamicin, ceftazidime, and imipenem. While P. aeruginosa has developed various levels of resistance to each of these, its response to ciprofloxacin is of particular interest because the drug is initially very effective, but P. aeruginosa rapidly acquires high-level resistance, rendering the drug impotent. In clinical isolates, approximately 30% of strains now present high-level ciprofloxacin resistance. ]

    ncbi.nlm.nih.gov/pmc/articles/PMC2976116/

    The WHO guidance on treating MDR-TB ranks the aminoglycosides as Group 2 -

    [ All patients should receive a second-line Group 2 injectable agent in the intensive phase of MDR-TB treatment unless resistance is documented or highly suspected. Either kanamycin, amikacin or capreomycin can be used as a first choice if all meet the criteria of “likely to be effective”. ]

    - and ranks the fluoroquinolones as Group 3 -

    [ Fluoroquinolones are often the most effective anti-TB drugs in an MDR-TB regimen.

    In the treatment of patients with MDR-TB, a later-generation fluoroquinolone rather than an earlier-generation fluoroquinolone should be used (conditional recommendation, very low quality evidence).

    Ciprofloxacin has weaker efficacy against TB than other fluoroquinolones and is not recommended as an anti-TB drug.

    Thus, for the fluoroquinolones, it is suggested that unless there is a strong indication for not doing so, all MDR-TB patients should be treated using ‘later-generation’ fluoroquinolones - levofloxacin or moxifloxacin. ]

  • ".... I've been long since orphan drug status for short stature was awarded and then let slip away... I thought they should have fought harder....."

    Could you please elaborate on this part of your post? iPlex, already approved for GHIS, is caught up in the patent litigation settlement for a little while yet. How could they have fought harder in your estimation?

    Thanks

  • When is the last time the short position was under 7% of outstanding shares?

    Sentiment: Buy

  • Reply to

    Terry - where did you buy INSM short shares?

    by arikaycerocks Mar 18, 2016 7:41 PM

    Huh?

    Sentiment: Strong Buy

  • 2.2 million shares held by insiders as well. The company has made it clear by their actions they despise retail investors.

    Sentiment: Strong Buy

  • Reply to

    The Only Solution

    by bohemianclubman Apr 27, 2016 11:01 AM

    Hi Bo, Have not posted for many months but still check in from time to time. Little has changed with the psycho but I would not respond to him and feed into his psychosis.
    He says little of value and is clearly a fraud and identiuy thief. If you or anyone wanted to spend some dollars you could have him identified and prosecuted, but why bother. He lives in his own confused universe of make believe as he will learn as the Ismed story reaches a climax this year. The power owners representing 90% of the shares know a slight bit more than any of us and they stand to gain anywhere from 300-500% in my opinion within 12 months.

    In the meantime I will check in from time to time but only respond to credible posters.
    Stay well and stay the course. I am.

    Sentiment: Strong Buy

  • +1. Anything in the 2-300k daily volume, and I figur only a few new buyers, or longs adding at these low prices, are actually buying and holding on. I've been long since orphan drug status for short stature was awarded and then let slip away... I thought they should have fought harder. But now we are very close to profiting, and I get a little guilty pleasure hoping someone loses their shorts (pun intended) when the price starts skyrocketing.

    Sentiment: Strong Buy

  • I'm as guilty as anyone - pointing out the disinformation and nonsensical statements posted 24 hours a day for years and years by the INSM message boards psychopathic poster.

    I was about to put up a post letting the others know that despite a myriad of posts that he went long (right at the bottom of course) but has purchased put protection, as we should all do, there is no open interest in the puts clearly illustrating yet another lie from the mouth of the greatest biotech trader of all time.

    But that is what he wants. Lives for. The most bizarre fetish ever.

    There are real events transpiring and coming up at INSM. The European decision, enrolling the U.S. phase III trial, new drugs using the liposomal technology, other disease that could be fought by LAI, the ever expanding number of patients being diagnosed with NTM, and of course the ever approaching end of the hold on their currently approved drug. All real, all things I come to this board to get the opinions of what I consider really intelligent posters.

    And so many of those opinions - bwd explaining the European approval process as well as many other important considerations - rocks with his well researched explanations for why he believes LAI could eventually treat a much larger patient population, etc. etc. get totally lost in the fray of psychotic babble brought on by bizarro boy.

    It's very hard and sometimes nearly impossible not to respond when I feel an opening to stomp on his statements, an easy avenue to verify his lies. I'm not going to respond anymore. I'm not going to feed his fetish. I'm still going to be here nearly daily reading the opinions of those I trust and respect. I have much invested here and still tremendous faith, but I'm going to resist that primal urge to pounce on statements made by the one with the lonely life.

    It's my opinion that that cannot feed there fetish will eventually look elsewhere, and if none here feed it the boil may go away.

  • 61.87 Million Share Outstanding. 89.6% Held by Intuitions. So, if 100,000 shares are in play that would represent 0.16% of the total shares.
    These up and downs by day traders are meaningless. Where we are on the approvals is what is important and should be the focus.

    Sentiment: Strong Buy

  • Reply to

    Terry - where did you buy INSM short shares?

    by arikaycerocks Mar 18, 2016 7:41 PM

    Jad, I used to point out spelling deficiencies, but it usually came back to bit me in the dupa......case in point.....shouldn't "grammerless" be "grammarless" if there is such a word?

    8-)

  • Reply to

    Terry - where did you buy INSM short shares?

    by arikaycerocks Mar 18, 2016 7:41 PM

    "Spelling deficient" is just the tip of the iceberg. He's about as close as it gets to being pan-deficient.

    Apart from a daily reminder of his limitations to pop his delusional bubble it's best to ignore his posts.

    Trading insults is futile. As that doesn't entail discussion it's in his "hit and run" comfort zone - one of the few things he can do without betraying his woefully low IQ.

  • Reply to

    Terry - your ARDM recommendation vs INSM

    by arikaycerocks Apr 26, 2016 6:31 PM

    Terry keeps bringing up barriers for Arikayce with the EMA. Namely:
    1) No supporting phase 3 trial results for NTM;
    2) Cannot ever pursue CF Pa because of TIP;
    3) CF is forever out-of-bounds for NTM because NTM patients with CF are excluded from the CONVERT.

    But I believe he (or one of his many ids) have pointed to Aradigm as an Insmed competitor with their Pulmaquin/Lipoquin products.

    I would like Terry to explain how Aradigm gets to the CF Pa market when their orphan designation is for non-cystic fibrosis bronchiectasis? Even their current phase 3 trials are for patients with non-cystic fibrosis bronchiectasis who have Pseudomonas aeruginosa (which is not NTM by the way)?

    If these kinds of hurdles exist for Arikayce, why don’t they exist for Pulmaquin? Seriously, because Aradigm is on my short list of potential company/product acquisitions for Insmed. I believe a scientific doorway to CF Pa exists for Aradigm; a door that is bigger than Arikayce’s similarity challenge, by the way; but, can Terry explain this coherently?

    I suspect he can only bash and try to deflect with his "everyone else posting here is the same person."

    bwd

  • Reply to

    Terry - your ARDM recommendation vs INSM

    by arikaycerocks Apr 26, 2016 6:31 PM

    Pulmaquin has always been on my list for an Insmed acquisition one way or another.

  • Reply to

    Price drop

    by ltdobanion Apr 26, 2016 3:57 PM

    Oh FFFFFk off

  • Reply to

    career job positions

    by iounothjing1 Apr 26, 2016 2:11 PM

    I don't know what else has been removed, but all of the summer intern jobs are now gone......

Must Watch
INSM
11.07-0.67(-5.71%)May 4 4:00 PMEDT